Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Merck
McKesson
McKinsey
Boehringer Ingelheim

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PRETOMANID


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pretomanid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed National Institute of Allergy and Infectious Diseases (NIAID) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT02256696 ↗ Assessing PA-824 for Tuberculosis (the APT Trial) Recruiting University of Cape Town Phase 2 2015-04-29 Assess the mycobactericidal activity of PA-824 (given at 200 mg daily) when added to first-line tuberculosis (TB) treatment (isoniazid, pyrazinamide, and a rifamycin antibiotic) over 12 weeks of treatment. Funding Source - FDA OOPD
NCT02256696 ↗ Assessing PA-824 for Tuberculosis (the APT Trial) Recruiting Johns Hopkins University Phase 2 2015-04-29 Assess the mycobactericidal activity of PA-824 (given at 200 mg daily) when added to first-line tuberculosis (TB) treatment (isoniazid, pyrazinamide, and a rifamycin antibiotic) over 12 weeks of treatment. Funding Source - FDA OOPD
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pretomanid

Condition Name

Condition Name for Pretomanid
Intervention Trials
Tuberculosis 6
Tuberculosis, Pulmonary 4
Extensively Drug-Resistant Tuberculosis 4
Tuberculosis, Multidrug-Resistant 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pretomanid
Intervention Trials
Tuberculosis 13
Tuberculosis, Multidrug-Resistant 9
Tuberculosis, Pulmonary 9
Extensively Drug-Resistant Tuberculosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pretomanid

Trials by Country

Trials by Country for Pretomanid
Location Trials
South Africa 25
United States 24
Uzbekistan 6
Belarus 4
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pretomanid
Location Trials
Missouri 3
Texas 2
North Carolina 2
California 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pretomanid

Clinical Trial Phase

Clinical Trial Phase for Pretomanid
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pretomanid
Clinical Trial Phase Trials
Recruiting 7
Active, not recruiting 4
Completed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pretomanid

Sponsor Name

Sponsor Name for Pretomanid
Sponsor Trials
Global Alliance for TB Drug Development 7
Wits Health Consortium (Pty) Ltd 4
London School of Hygiene and Tropical Medicine 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pretomanid
Sponsor Trials
Other 90
NIH 7
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
McKinsey
Boehringer Ingelheim
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.